ArticleCancer control : journal of the Moffitt Cancer Center
Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Emerging Roles of mFrontiers in oncology · 2022Pooled it
- Identification and exploration of potential N6-methylation related mRNAs in endometriosis.Frontiers in genetics · 2026Article
- mFrontiers in cell and developmental biology · 2026Review
- Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.Cell death discovery · 2025Review
- Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects.Frontiers in oncology · 2024Review
- The potential regulatory role of RNA methylation in ovarian cancer.RNA biology · 2023Review
- Roles of NExperimental hematology & oncology · 2022Review
- Effects of NFrontiers in oncology · 2022Review
- The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer.Annals of translational medicine · 2022Article
- A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.Frontiers in genetics · 2022Article
- RNA m6A methylation regulators in ovarian cancer.Cancer cell international · 2021Review
- Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.Cancer cell international · 2021Article
- Gene Signatures and Prognostic Values of N6-Methyladenosine Related Genes in Ovarian Cancer.Frontiers in genetics · 2021Article
- Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN6-methyladenosine (m6A) is the most common form of mRNA modification under the field of "RNA epigenetics." However, its role in ovarian cancer (OC) development is poorly understood. In the current study, we aimed to identify gene signatures and prognostic values of m6A RNA methylation regulators.
methodSpecifically, we downloaded Mutations and Copy number variant (CNV) data from the TCGA database for 579 OC patients, then analyzed gene expression and prognosis value using integrative bioinformatics. Thereafter, we verified the related biological processes of Wilms' tumor 1-associating protein (WTAP) gene using Gene set enrichment analysis (GSEA).
resultsResults showed that almost all ovarian cancer patients (99.31%) have CNVs with at least 1 m6A regulatory gene, whereas 83.76% of cases exhibited concurrence of CNVs in more than 4 m6A regulatory genes. Additionally, alteration of m6A regulators was associated with historical grade, whereas integrative bioinformatics and Cox multivariate model analysis revealed a significant correlation between high WTAP expression and worse ovarian cancer outcomes. Moreover, GSEA revealed that high WTAP expression was associated with cell cycle regulation and MYC targets.
conclusionOverall, our findings demonstrate the significance of high-frequency genetic alterations of m6A RNA methylation regulators and WTAP's poor prognosis value in OC. These findings provide valuable insights into the role of m6A methylation in OC, and will be vital in guiding development of novel treatment therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.